Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Perianal Fistula, Cryptoglandular Perianal Fistula
Interventions: MSC-AFP; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Hepatitis C Virus Infection
Interventions: CTS-1027, Placebo; Drug · Other
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more

Conditions: Self-preformed Hand Examination
Interventions: Physician-oriented Video, Patient-oriented video; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Colorectal Cancer
Interventions: sunitinib and capecitabine; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Select Advanced Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cataract
Interventions: Model SN60WF, Model MA60AC; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glioblastoma, Gliosarcoma, Brain Tumor
Interventions: radiosurgery, bevacizumab, irinotecan hydrochloride; Radiation · Biological · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Carcinoma, Radiation-Induced Dermatitis
Interventions: Best Practice, Quality-of-Life Assessment, Topical Keratin; Other · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Critical Illness, Respiratory Failure, Myopathy, Weakness
Interventions: Sham Treatment, Electrical stimulation; Device
Lead sponsor: Gerald Supinski; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Asthma
Interventions: Not listed
Lead sponsor: American Academy of Family Physicians; Other
Eligibility: 12 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Leawood, Kansas

Conditions: Urologic Diseases, Antibacterial Drug Adverse Reaction
Interventions: Audit-and-feedback; Behavioral
Lead sponsor: Iowa City Veterans Affairs Medical Center; Federal
Eligibility: Not listed
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • New York, New York

Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: bevacizumab, temsirolimus; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Prostate Cancer
Interventions: Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI); Drug · Device
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Medication Adherence, Blood Pressure
Interventions: Medication reminder; Device
Lead sponsor: Purdue University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: DCI 1020; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, idarubicin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 2,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 32
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy; Biological · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions: everolimus, bendamustine hydrochloride; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anxiety
Interventions: Acamprosate; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Adherence, Patient
Interventions: Immulina; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Urologic Diseases
Interventions: Stream Dx, DFree, TestCard; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Lenalidomide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions: Neuropeptide Y, Placebo; Drug · Other
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Valhalla, New York

Search by objective public record fields.

Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)

Study of CTS-1027 in Hepatitis C Patients

Engaging Patients for Physical Exams During Virtual Care Visits

Sunitinib and Capecitabine for First Line Colon Cancer

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).

Radiosurgery Plus Bevacizumab in Glioblastoma

Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

Treatment of Muscle Weakness in Critically Ill Patients

To Evaluate the Use of ASTHMA IQ in a Primary Care Setting

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

The Effect of Medication Reminder Technology on Medication Adherence and Hypertension Outcomes

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans

Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder